CDNA:NSD-CareDx, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 64.91

Change

+3.56 (+5.80)%

Market Cap

USD 3.02B

Volume

0.46M

Average Target Price

USD 50.92 (-21.55%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+4.66 (+1.35%)

USD50.52B 80.20 40.84
IDXX IDEXX Laboratories, Inc

-2.92 (-0.63%)

USD39.24B 80.21 54.04
DXCM DexCom, Inc

+3.40 (+0.99%)

USD33.09B 142.47 81.96
EXAS Exact Sciences Corporation

+2.20 (+1.68%)

USD19.66B N/A N/A
GH Guardant Health, Inc

+1.65 (+1.35%)

USD12.20B N/A N/A
ICLR ICON Public Limited Company

+1.17 (+0.59%)

USD10.52B 33.14 21.15
OZON Ozon Holdings PLC

-1.48 (-3.00%)

USD8.84B N/A N/A
QDEL Quidel Corporation

-7.42 (-3.69%)

USD8.46B 23.54 14.71
NTRA Natera, Inc

-1.50 (-1.69%)

USD7.60B N/A N/A
PRAH PRA Health Sciences, Inc

+2.93 (+2.64%)

USD7.11B 32.42 18.57

ETFs Containing CDNA

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 200.93% 87% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 200.93% 87% B+ 94% A
Trailing 12 Months  
Capital Gain 206.03% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 206.03% 87% B+ 93% A
Trailing 5 Years  
Capital Gain 901.70% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 901.70% 95% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 174.64% N/A N/A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 174.64% N/A N/A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 317.78% N/A N/A 3% F
Risk Adjusted Return 54.96% N/A N/A 74% C
Market Capitalization 3.02B 72% C- 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.82 19% F 12% F
Price / Cash Flow Ratio -1,091.34 100% A+ 99% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -10.91% 61% D- 41% F
Return on Invested Capital -23.14% 52% F 27% F
Return on Assets -5.34% 59% F 32% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.35 12% F 11% F
Short Percent 11.62% 16% F 19% F
Beta 0.80 75% C 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector